Sarepta Therapeutics, Inc.
SRPT
Price:
$144.24
Market Cap:
$13.63B
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping tech...[Read more]
Industry
Biotechnology
IPO Date
1997-06-04
Stock Exchange
NASDAQ
Ticker
SRPT
The PE Ratio as of July 2024 (TTM) for Sarepta Therapeutics, Inc. (SRPT) is 335.44
According to Sarepta Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is 335.44. This represents a change of -3543.44% compared to the average of -9.74 of the last 4 quarters.
Sarepta Therapeutics, Inc. (SRPT) Historical PE Ratio (quarterly & annually)
How has SRPT PE Ratio performed in the past?
The mean historical PE Ratio of Sarepta Therapeutics, Inc. over the last ten years is -18.87. The current 335.44 PE Ratio has changed -177852.08% with respect to the historical average. Over the past ten years (40 quarters), SRPT's PE Ratio was at its highest in in the March 2024 quarter at 83.53. The PE Ratio was at its lowest in in the March 2020 quarter at -106.33.
Average
-18.87
Median
-16.38
Minimum
-64.56
Maximum
-4.27
Sarepta Therapeutics, Inc. (SRPT) PE Ratio by Quarter and Year
Discovering the peaks and valleys of Sarepta Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.19%
Maximum Annual PE Ratio = -4.27
Minimum Annual Increase = -69.06%
Minimum Annual PE Ratio = -64.56
| Year | PE Ratio | Change |
|---|---|---|
| 2023 | -16.62 | 3.07% |
| 2022 | -16.13 | -7.70% |
| 2021 | -17.47 | -27.15% |
| 2020 | -23.98 | 80.55% |
| 2019 | -13.28 | -33.50% |
| 2018 | -19.98 | -69.06% |
| 2017 | -64.56 | 1.19% |
| 2016 | -5.00 | -32.62% |
| 2015 | -7.42 | 73.85% |
| 2014 | -4.27 | -30.69% |
Sarepta Therapeutics, Inc. (SRPT) Average PE Ratio
How has SRPT PE Ratio performed in the past?
The current PE Ratio of Sarepta Therapeutics, Inc. (SRPT) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-16.74
5-year avg
-17.50
10-year avg
-18.87
Sarepta Therapeutics, Inc. (SRPT) PE Ratio vs. Peers
How is SRPT’s PE Ratio compared to its peers?
Sarepta Therapeutics, Inc.’s PE Ratio is greater than Reata Pharmaceuticals, Inc. (-89.36), greater than Mirati Therapeutics, Inc. (-5.32), greater than Krystal Biotech, Inc. (105.76), greater than Intercept Pharmaceuticals, Inc. (-13.55), greater than PTC Therapeutics, Inc. (-4.50), greater than Iovance Biotherapeutics, Inc. (-5.48), greater than Madrigal Pharmaceuticals, Inc. (-12.81), greater than Viking Therapeutics, Inc. (-75.29), greater than Hepion Pharmaceuticals, Inc. (-0.10), less than Terns Pharmaceuticals, Inc. (0), greater than Akero Therapeutics, Inc. (-7.36), greater than null (-9.30),
| Company | PE Ratio | Market cap |
|---|---|---|
| -89.36 | $6.57B | |
| -5.32 | $4.12B | |
| 105.76 | $6.10B | |
| -13.55 | $794.69M | |
| -4.50 | $2.61B | |
| -5.48 | $2.59B | |
| -12.81 | $6.06B | |
| -75.29 | $7.28B | |
| -0.10 | $4.61M | |
| 0 | $582.74M | |
| -7.36 | $1.94B | |
| -9.30 | $0 |
Build a custom stock screener for Sarepta Therapeutics, Inc. (SRPT) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Sarepta Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Sarepta Therapeutics, Inc. (SRPT) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Sarepta Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the PE Ratio?
How can you use the PE Ratio?
What is Sarepta Therapeutics, Inc.'s PE Ratio?
How is the PE Ratio calculated for Sarepta Therapeutics, Inc. (SRPT)?
What is the highest PE Ratio for Sarepta Therapeutics, Inc. (SRPT)?
What is the 3-year average PE Ratio for Sarepta Therapeutics, Inc. (SRPT)?
What is the 5-year average PE Ratio for Sarepta Therapeutics, Inc. (SRPT)?
How does the current PE Ratio for Sarepta Therapeutics, Inc. (SRPT) compare to its historical average?